Novolog (Pharm UP 1966) Ltd. (IL:NVLG)
TASE:NVLG
Want to see IL:NVLG full AI Analyst Report?
NVLG Stock Chart & Stats
126.20
>-0.01(-0.31%)
At close: 4:00 PM EST
126.20
>-0.01(-0.31%)
Day’s Range― - ―
52-Week Range82.70 - 154.63
Previous CloseN/A
Volume351.22K
Average Volume (3M)641.09K
Market Cap
₪426.58M
Enterprise Value488.02M
Total Cash (Recent Filing)₪121.77M
Total Debt (Recent Filing)₪183.20M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
May 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.05%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding510,874,760
10 Day Avg. Volume285,794
30 Day Avg. Volume641,093
Financial Highlights & Ratios
PEG Ratio-1.74
Price to Book (P/B)1.80
Price to Sales (P/S)0.36
P/FCF Ratio-18.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthManageable leverage (~0.5x debt/equity) provides balance-sheet resilience, lowering default and refinancing risk and giving flexibility to fund operations or absorb shocks while cash flows recover. This durable capital structure supports long-term operational continuity and investment capacity.
Cash Generation Track RecordCompany produced strong cash flow in prior years (operating ~158.5M, FCF ~99.8M in 2024), demonstrating underlying cash conversion capability. That track record indicates the business can generate substantial cash when conditions normalize, supporting reinvestment, dividends or debt reduction over months.
Proven ProfitabilityDemonstrated profitability across multiple years (2020–2022 and 2024) shows the business model can sustain margins and generate earnings. This recurring profitability suggests operational viability and that recent weakness may be cyclical rather than structural, supporting potential recovery over a multi-month horizon.
Bears Say
Revenue & Earnings Collapse (2025)Sharp 2025 revenue decline (-14.9%) and net income collapse (~4.1M vs ~39.5M) indicate structural demand, pricing or competitive pressures that materially erode core earnings. Such a swift drop can weaken market position, reduce scale economics and lengthen recovery timeframes absent strategic fixes.
Cash Flow ReversalOperating cash flow turned negative (~-16.5M) and FCF fell to ~-34.2M in 2025, reversing prior strong cash generation. Sustained cash-flow deficits force reliance on financing or asset sales, constrain reinvestment, and elevate liquidity and refinancing risk over the coming months.
Earnings VolatilityEarnings volatility, including a loss in 2023, reflects unstable demand or a cost base that struggles in downturns. This reduces forecasting reliability, increases financing and strategic planning risk, and makes consistent capital allocation, dividends or sustained investment programs harder to commit to over medium term horizons.
Novolog News
NVLG FAQ
What was Novolog (Pharm UP 1966) Ltd.’s price range in the past 12 months?
Novolog (Pharm UP 1966) Ltd. lowest stock price was 82.70 and its highest was 154.63 in the past 12 months.
What is Novolog (Pharm UP 1966) Ltd.’s market cap?
Novolog (Pharm UP 1966) Ltd.’s market cap is ₪426.58M.
When is Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date?
Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date is May 25, 2026 which is in 2 days.
How were Novolog (Pharm UP 1966) Ltd.’s earnings last quarter?
Novolog (Pharm UP 1966) Ltd. released its earnings results on Nov 12, 2025. The company reported 0.8 earnings per share for the quarter, beating the consensus estimate of N/A by 0.8.
Is Novolog (Pharm UP 1966) Ltd. overvalued?
According to Wall Street analysts Novolog (Pharm UP 1966) Ltd.’s price is currently Overvalued.
Does Novolog (Pharm UP 1966) Ltd. pay dividends?
Novolog (Pharm UP 1966) Ltd. pays a Quarterly dividend of 1.957 which represents an annual dividend yield of 3.05%. See more information on Novolog (Pharm UP 1966) Ltd. dividends here
What is Novolog (Pharm UP 1966) Ltd.’s EPS estimate?
Novolog (Pharm UP 1966) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novolog (Pharm UP 1966) Ltd. have?
Novolog (Pharm UP 1966) Ltd. has 510,874,760 shares outstanding.
What happened to Novolog (Pharm UP 1966) Ltd.’s price movement after its last earnings report?
Novolog (Pharm UP 1966) Ltd. reported an EPS of 0.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novolog (Pharm UP 1966) Ltd.?
Currently, no hedge funds are holding shares in IL:NVLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novolog (Pharm UP 1966) Ltd.
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.